News

Approximately 1 in 5 newly diagnosed patients are initiating direct acting antivirals within 6 months, according to Medicaid data review.

These new findings suggest the COMSA parameters may have applicability for standardizing observational studies’ results for pediatric patients with asthma.

A Mayo Clinic study shows FMT may provide benefit for patients experiencing recurrent infections during their C difficile treatment.

The data from this analysis indicates that for those with psoriasis, effective and long-term continuous control of the skin disease could diminish risk of CCVD risk.

Presented at ASRS 2023, results from the phase 2 ZETA-1 trial showed oral APX3330 missed its primary endpoint, but the consideration of a binocular treatment effect may warrant further clinical development.

The approval is the second granted to a geographic atrophy drug that targets the complement pathway.

The apparent risk increases for use of these medications over the past 2 decades suggests the global importance of health care reforms and focus on drug safety.

Clayton, a primary investigator in the drug's pivotal trials, discusses what the historic FDA approval means for managing PPD in women.

The approval marks the first indication for a postpartum depression drug—one that which has been touted for its rapid-acting effect and sustained benefits.

The results found those with sexual minority status were significantly more likely to attend prenatal care visits (20%) when compared with heterosexual women.

Presented at ASRS 2023, results from FARETINA-AMD suggest positive early treatment patterns and outcomes in patients with nAMD initiating faricimab treatment.

This expanded upon the limited data available on risks of precautionary allergen label food introduction for those with allergies, the results of which suggest new possibilities for future allergy management.

This interview with Dr. Chovatiya featured a discussion about new findings from a recent study on epidemiologic data on vitiligo in the US.

The biosimilar month in review highlights the July 1 launch of 7 adalimumab (Humira) biosimilars in the US and the cost-saving potential of increased biosimilar availability.

Qazi reviews the selective JAK1 inhibitor's benefit for patients who previously failed TNF inhibitor regimen.

Presented at ASRS 2023, study data showed a single, in-office injection of RGX-314 gene therapy may have long-lasting improvements in diabetic retinopathy severity.

While tele-CBT did not lead to significant changes in short-term weight outcomes, it was effective in improving disordered eating behaviors and reducing psychological distress.

Presented at ASRS 2023, additional results from the Pagoda and Pavilion trials suggest a potential benefit of PDS for patients with DME and diabetic retinopathy.

"Depression causes a large public health burden, and alcohol-related behavior is a potentially modifiable risk factor," Dr. Gemma Hammerton writes.

This new data indicates that dupilumab in this patient population had favorable efficacy and safety, though some unique concerns were risk of infection and eosinophilia.

This cardiology case report features a woman in her mid 40s reporting chest pain and palpitations. Check out the ECG and determine the most likely rhythm in this patient!

The data from this new study may indicate home NBUVB treatment effectiveness and other benefits such as financial, convenience, and medical benefits.

An analysis of real-world data provides an overview of the effects of GLP-1 receptor agonist and SGLT2 inhibitor use among adults with type 1 diabetes.

At the 48-hour mark, the mean difference between high-dose VX-548 and placebo was 37.8 in the abdominoplasty group and 36.8 in the bunionectomy group, thus demonstrating the drug's pain relief potential.

A multinational study shows people who achieve sustained virologic response still face a 3-fold greater risk or more of mortality due to liver disease or drug-related issues.

The baseline data for the initial 1000 participants recruited into the TX-YDSRN show 79.6% were diagnosed with a primary depressive disorder.

Presented at ASRS 2023, results from the GALE extension study showed crossover to pegcetacoplan treatment from sham stabilized photoreceptor degeneration over 6 months.

Investigators discuss the potential of psychedelic drugs as a new approach to treating mental illnesses, highlighting their therapeutic benefits and the need for further research to understand their effects, safety, and accessibility.